Shionogi & Co., Ltd - SH0

Shionogi & Co., Ltd. engages in the research, development, manufacture, and marketing of pharmaceuticals, diagnostic reagents, and medical devices in Japan and internationally. The company primarily focuses on metabolic syndrome, pain, infectious diseases, cholesterol medication, anti-hypertension drugs, depression treatment, prescription drugs, OTC drugs, and diagnostics. It has a research collaborative agreement with National University Corporation Kyoto University to focus on drug discovery and medical research for the treatment of psychiatric disorders; and strategic collaboration with Sage Therapeutics, Inc., as well as a license agreement with Hsiri Therapeutics Inc. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.